Illumina, Inc.
Illumina Reports First Quarter 2024 Financial Results
Summary
Illumina, Inc. announced its financial results for the first quarter of fiscal year 2024. Core Illumina revenue was $1.06 billion, down 2% year-over-year, with a Core Illumina GAAP operating margin of 11.0% and a non-GAAP operating margin of 20.6%. Consolidated revenue was $1.08 billion, down 1% year-over-year. The company reported a GAAP diluted loss per share of ($0.79) and a non-GAAP diluted earnings per share of $0.09. Illumina reiterated its fiscal year 2024 revenue guidance and expects Core Illumina non-GAAP operating margin to be approximately 20%. The company remains on track to divest GRAIL by the end of Q2 2024.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement